Tokyo, Dec. 12 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060049) titled 'Prospective observational study of quality of life and work productivity in people treated with obesity medications' on Dec. 11.
Study Type:
Observational
Primary Sponsor:
Institute - Kobe University
Condition:
Condition - Obesity disease
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To prospectively evaluate changes in obesity-related quality of life and work productivity, and their association with body weight change, in patients with obesity treated with semaglutide or tirzepatide.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1. 18 years of age or older
2. Individuals newly initiating use of semaglutide (Ugovi) or tirzepatide (Zepbound) as obesity treatment drugs
3. Individuals who have provided written consent for this study
Key exclusion criteria - 1. Individuals who have difficulty completing the questionnaire
2. Individuals undergoing treatment for malignant tumors
3. Individuals undergoing dialysis
4. Individuals who are pregnant or wish to become pregnant
5. Individuals who have undergone weight loss/metabolic improvement surgery (such as sleeve gastrectomy) or who are scheduled to undergo such surgery
6. Individuals suspected of off-label use
7. Individuals deemed inappropriate for this study by the principal investigator
Target Size - 140
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 01 Month 19 Day
Anticipated trial start date - 2026 Year 04 Month 01 Day
Last follow-up date - 2026 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068617
Disclaimer: Curated by HT Syndication.
